Endpoint Validation Study (0524A-015)
Endpoint Validation Study (0524A-015)
To determine the most effective daily dose of MK0524A when compared with placebo after the
 8-week treatment period for Niacin Induce Flushing (NIF).
Inclusion Criteria:

 -  Patients must be male or female between 18 to 70 years

 -  Qualified women must be sterile (through surgery) and/or post-menopausal, and/or agree
 to use birth control

 Exclusion Criteria:

 -  You are a woman who is having hot flashes, receiving Hormone Replacement Therapy
 (HRT), and/or other therapies for hot flashes

 -  You are currently using Niacin/or Niacin containing products with a daily dose over 50
 mg/day

 -  You are sensitive to niacin

 -  You have a history gout

 -  You drink more than 2 glasses of alcohol per day and you are not willing to stop

 -  You don't have access to a telephone